Publication

Increased survival of non low-grade and deep-seated soft tissue sarcoma after surgical management in high-volume hospitals: a nationwide study from the Netherlands.

Vos, M., Blaauwgeers, H. G. T., Ho, V., Van Houdt, W., van der Hage, J. A., Been, L., Bonenkamp, H. J., Bemelmans, MHA., Van Dalen, T., Haas, R. L. M., Grunhagen, D. J. & Verhoef, C., 16-Feb-2019, In : European Journal of Cancer. 110, p. 98-106 9 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Vos, M., Blaauwgeers, H. G. T., Ho, V., Van Houdt, W., van der Hage, J. A., Been, L., ... Verhoef, C. (2019). Increased survival of non low-grade and deep-seated soft tissue sarcoma after surgical management in high-volume hospitals: a nationwide study from the Netherlands. European Journal of Cancer, 110, 98-106. https://doi.org/10.1016/j.ejca.2019.01.005

Author

Vos, Melissa ; Blaauwgeers, H.G.T. ; Ho, Vincent ; Van Houdt, Winan ; van der Hage, Jos A. ; Been, Lukas ; Bonenkamp, Han J. ; Bemelmans, MHA ; Van Dalen, Thijs ; Haas, Rick L M ; Grunhagen, Dirk J. ; Verhoef, Cees. / Increased survival of non low-grade and deep-seated soft tissue sarcoma after surgical management in high-volume hospitals : a nationwide study from the Netherlands. In: European Journal of Cancer. 2019 ; Vol. 110. pp. 98-106.

Harvard

Vos, M, Blaauwgeers, HGT, Ho, V, Van Houdt, W, van der Hage, JA, Been, L, Bonenkamp, HJ, Bemelmans, MHA, Van Dalen, T, Haas, RLM, Grunhagen, DJ & Verhoef, C 2019, 'Increased survival of non low-grade and deep-seated soft tissue sarcoma after surgical management in high-volume hospitals: a nationwide study from the Netherlands.' European Journal of Cancer, vol. 110, pp. 98-106. https://doi.org/10.1016/j.ejca.2019.01.005

Standard

Increased survival of non low-grade and deep-seated soft tissue sarcoma after surgical management in high-volume hospitals : a nationwide study from the Netherlands. / Vos, Melissa; Blaauwgeers, H.G.T.; Ho, Vincent; Van Houdt, Winan; van der Hage, Jos A.; Been, Lukas; Bonenkamp, Han J.; Bemelmans, MHA; Van Dalen, Thijs; Haas, Rick L M; Grunhagen, Dirk J.; Verhoef, Cees.

In: European Journal of Cancer, Vol. 110, 16.02.2019, p. 98-106.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Vos M, Blaauwgeers HGT, Ho V, Van Houdt W, van der Hage JA, Been L et al. Increased survival of non low-grade and deep-seated soft tissue sarcoma after surgical management in high-volume hospitals: a nationwide study from the Netherlands. European Journal of Cancer. 2019 Feb 16;110:98-106. https://doi.org/10.1016/j.ejca.2019.01.005


BibTeX

@article{b9818b45430247edb89abf34e308990a,
title = "Increased survival of non low-grade and deep-seated soft tissue sarcoma after surgical management in high-volume hospitals: a nationwide study from the Netherlands.",
abstract = "BACKGROUND: Diagnosing and treating soft tissue sarcomas (STSs) remains challenging, stressing the urgency for centralisation. This nationwide survey aimed to evaluate the centralisation of STS surgery and its effect on survival. METHODS: Patients operated for primary STS from 2006 to 2015 were queried from the Netherlands Cancer Registry. Hospitals in which STS surgery was performed were allocated into three categories: low-volume (1-9 resections per year), medium-volume (10-19 resections) or high-volume (≥20 resections). Differences in tumour characteristics and outcome were calculated. A multivariable regression analysis was performed to adjust for case-mix. RESULTS: Of the 5282 identified patients, 42{\%} was treated in low-volume hospitals, 7.7{\%} in medium-volume hospitals and 51{\%} in high-volume hospitals, with a significant trend over time towards treatment in a high-volume hospital (p < 0.01). In high-volume hospitals, more often patients with non low-grade, large and deep-seated tumours were treated than in low-volume hospitals. For the whole group, there was no survival benefit for patients treated in high-volume hospitals, with 10-year net survival rates of 76{\%} (low-volume), 68{\%} (medium-volume) and 68{\%} (high-volume). However, subgroup analysis for patients with non low-grade and deep-seated tumours did reveal a benefit from treatment in a high-volume hospitals with 10-year survival rates of 54{\%} (high-volume), 49{\%} (low-volume) and 42{\%} (medium-volume) and a relative risk of 1.3 (high-volume versus low-volume, p = 0.03). CONCLUSION: Centralisation of STS surgery has increased in the past decade. Surgery in a high-volume hospital improved survival of patients with non low-grade and deep-seated tumours, and therefore these patients should be referred to such a hospital.",
keywords = "DIAGNOSIS",
author = "Melissa Vos and H.G.T. Blaauwgeers and Vincent Ho and {Van Houdt}, Winan and {van der Hage}, {Jos A.} and Lukas Been and Bonenkamp, {Han J.} and MHA Bemelmans and {Van Dalen}, Thijs and Haas, {Rick L M} and Grunhagen, {Dirk J.} and Cees Verhoef",
year = "2019",
month = "2",
day = "16",
doi = "10.1016/j.ejca.2019.01.005",
language = "English",
volume = "110",
pages = "98--106",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "ELSEVIER SCI LTD",

}

RIS

TY - JOUR

T1 - Increased survival of non low-grade and deep-seated soft tissue sarcoma after surgical management in high-volume hospitals

T2 - a nationwide study from the Netherlands.

AU - Vos, Melissa

AU - Blaauwgeers, H.G.T.

AU - Ho, Vincent

AU - Van Houdt, Winan

AU - van der Hage, Jos A.

AU - Been, Lukas

AU - Bonenkamp, Han J.

AU - Bemelmans, MHA

AU - Van Dalen, Thijs

AU - Haas, Rick L M

AU - Grunhagen, Dirk J.

AU - Verhoef, Cees

PY - 2019/2/16

Y1 - 2019/2/16

N2 - BACKGROUND: Diagnosing and treating soft tissue sarcomas (STSs) remains challenging, stressing the urgency for centralisation. This nationwide survey aimed to evaluate the centralisation of STS surgery and its effect on survival. METHODS: Patients operated for primary STS from 2006 to 2015 were queried from the Netherlands Cancer Registry. Hospitals in which STS surgery was performed were allocated into three categories: low-volume (1-9 resections per year), medium-volume (10-19 resections) or high-volume (≥20 resections). Differences in tumour characteristics and outcome were calculated. A multivariable regression analysis was performed to adjust for case-mix. RESULTS: Of the 5282 identified patients, 42% was treated in low-volume hospitals, 7.7% in medium-volume hospitals and 51% in high-volume hospitals, with a significant trend over time towards treatment in a high-volume hospital (p < 0.01). In high-volume hospitals, more often patients with non low-grade, large and deep-seated tumours were treated than in low-volume hospitals. For the whole group, there was no survival benefit for patients treated in high-volume hospitals, with 10-year net survival rates of 76% (low-volume), 68% (medium-volume) and 68% (high-volume). However, subgroup analysis for patients with non low-grade and deep-seated tumours did reveal a benefit from treatment in a high-volume hospitals with 10-year survival rates of 54% (high-volume), 49% (low-volume) and 42% (medium-volume) and a relative risk of 1.3 (high-volume versus low-volume, p = 0.03). CONCLUSION: Centralisation of STS surgery has increased in the past decade. Surgery in a high-volume hospital improved survival of patients with non low-grade and deep-seated tumours, and therefore these patients should be referred to such a hospital.

AB - BACKGROUND: Diagnosing and treating soft tissue sarcomas (STSs) remains challenging, stressing the urgency for centralisation. This nationwide survey aimed to evaluate the centralisation of STS surgery and its effect on survival. METHODS: Patients operated for primary STS from 2006 to 2015 were queried from the Netherlands Cancer Registry. Hospitals in which STS surgery was performed were allocated into three categories: low-volume (1-9 resections per year), medium-volume (10-19 resections) or high-volume (≥20 resections). Differences in tumour characteristics and outcome were calculated. A multivariable regression analysis was performed to adjust for case-mix. RESULTS: Of the 5282 identified patients, 42% was treated in low-volume hospitals, 7.7% in medium-volume hospitals and 51% in high-volume hospitals, with a significant trend over time towards treatment in a high-volume hospital (p < 0.01). In high-volume hospitals, more often patients with non low-grade, large and deep-seated tumours were treated than in low-volume hospitals. For the whole group, there was no survival benefit for patients treated in high-volume hospitals, with 10-year net survival rates of 76% (low-volume), 68% (medium-volume) and 68% (high-volume). However, subgroup analysis for patients with non low-grade and deep-seated tumours did reveal a benefit from treatment in a high-volume hospitals with 10-year survival rates of 54% (high-volume), 49% (low-volume) and 42% (medium-volume) and a relative risk of 1.3 (high-volume versus low-volume, p = 0.03). CONCLUSION: Centralisation of STS surgery has increased in the past decade. Surgery in a high-volume hospital improved survival of patients with non low-grade and deep-seated tumours, and therefore these patients should be referred to such a hospital.

KW - DIAGNOSIS

U2 - 10.1016/j.ejca.2019.01.005

DO - 10.1016/j.ejca.2019.01.005

M3 - Article

VL - 110

SP - 98

EP - 106

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -

ID: 77074821